Alivus Life Sciences Reports Robust Q2 FY27 Operating Performance and Margin Expansion
Alivus Life Sciences Ltd · Investor Presentation · 30 Oct 2026, 1:05 am
Alivus Life Sciences Reports Robust Q2 FY27 Operating Performance and Margin Expansion Alivus Life Sciences reported Q2 FY27 revenue from operations of ₹6,820 Mn, rising 16.0% YoY and 6.5% QoQ, driven by a 20.8% YoY surge in non-GPL revenue to ₹5,369 Mn (79% of total). EBITDA surged 47.0% YoY to ₹2,851 Mn, with EBITDA margin expanding 880 bps YoY to 41.8% on operational efficiencies and favorable mix. PAT rose 51.3% YoY to ₹1,968 Mn. Strong free cash flow of ₹2,702 Mn lifted cash balances to ₹10,116 Mn as of 30th Sep'26. Total reactor capacity is projected to expand from 1,424 KL to 2,150 KL by FY27E.
Original exchange filing (PDF)
More announcements from Alivus Life Sciences Ltd
- Enclosed please find herewith update on acquisition. · 11 Nov 2026
- Please find enclosed herewith disclosure under Regulation 30 of SEBI(LODR), 2015. · 11 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Nirma Ltd · 07 Nov 2026
- Please find attached herewith submission with respect to transcript of the earning call. · 06 Nov 2026
- Please find enclosed herewith intimation for Analyst/Investor meeting. · 04 Nov 2026
- Please find enclosed herewith intimation for Analyst/Investor Meet. · 30 Oct 2026
- We hereby confirm that we have uploaded audio recording of the Q2 FY2027 Earnings Call held on October 30, 2026 on the website of the Company. · 30 Oct 2026
- Please find enclosed herewith intimation with respect to allotment of equity shares under "Employee Stock Option Scheme, 2021" · 30 Oct 2026
